Latest Prothrombin time Stories
NEW ORLEANS, Dec. 6 /PRNewswire-USNewswire/ -- Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment. Research presented today at the 51st Annual Meeting of the American Society of Hematology reveals that the practice of using the anticoagulants aspirin...
BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events than patients given edoxaban twice a day (BID). The analysis finds that bleeding associated with edoxaban is most closely correlated with minimum concentration levels of the drug...
Researchers from Boston University School of Medicine (BUSM) have determined the optimal dose-management strategy to derive maximal benefit from warfarin therapy and improve patient outcomes. Results of the study appear online in the December 2008 issue of the Journal of Thrombosis and Haemostasis.Warfarin is highly effective to prevent strokes, treat venous thromboembolism and for other conditions. Numerous studies have focused on the underutilization of warfarin for patients with atrial...
SAN FRANCISCO, Dec. 7 /PRNewswire-USNewswire/ -- The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy will be presented in a press conference on Sunday, December 7, at 9:30 a.m., during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Additional research being featured at the press conference includes studies that examine the use of three...
SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Patients with non-valvular atrial fibrillation receiving either 30 mg or 60 mg once-daily dose of DU-176b, an investigational oral Factor Xa inhibitor, experienced comparable safety and tolerability compared to those taking warfarin, according to new Phase II data presented today at the 50th Annual Meeting of the American Society of Hematology in San Francisco. These findings are the first results from a Phase II clinical study evaluating...
ARYx Therapeutics, a biopharmaceutical company, has completed enrollment in EmbraceAC, a Phase II/III double-blind clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level of anticoagulation as measured by international normalized ratio (INR). Based upon recent...
ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced it has completed enrollment in EmbraceAC, a Phase 2/3 double-blind clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level of anticoagulation as measured by INR (International Normalized...
People who take the blood thinning drug warfarin may have larger amounts of bleeding in the brain and increased risk of death, U.S. researchers said. Study author Dr. Matthew L. Flaherty of the University of Cincinnati said warfarin is commonly prescribed to prevent blood clotting to prevent heart attacks. Studies have shown it helps prevent ischemic stroke for patients with an abnormal heart rhythm called atrial fibrillation. However, if the drug makes the blood too thin, it can increase the...
Inverness Medical Physician Diagnostics Group, a division of Inverness Medical Innovations, has launched the INRatio2 PT/INR monitoring system, a portable device that measures blood-clotting time, also known as prothrombin time, using one drop of blood from a patient's finger. The INRatio2 is used by healthcare professionals and their patients in the management of warfarin, a blood-thinning drug, to monitor the effectiveness of the drug and warn of potential blood clots and other bleeding...
Inverness Medical Physician Diagnostics Group, a division of Inverness Medical Innovations, today announced the launch of the INRatio(R)2 PT/INR Monitoring System, a portable device that measures blood-clotting time, also known as prothrombin time, using one drop of blood from a patient's finger. The INRatio2 is used by healthcare professionals and their patients in the management of warfarin, a blood-thinning drug, to monitor the effectiveness of the drug and warn of potential blood clots...
